DeepMed Research

Jiangsu Province Centers for Disease Control and Prevention

People's Republic of China

Country: People's Republic of China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.jstd.gov.cn/

Clinical Trials

Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children

Phase 3

Completed

Conditions: Group A, C Polysaccharide Meningitis
Type b Haemophilus Influenza

Interventions: Biological: A+C+hib Conjugate Vaccine
Biological: A+C Vaccine
Biological: Placebo
Biological: Hib vaccine

First Posted Date: 2011-09-05

Last Posted Date: 2012-04-19

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 2394

Registration Number: NCT01428908

Locations: 🇨🇳
Funing county Center for Disease Control and Prevention, Funing county, Jiangsu, China

Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: 0.5ml/dose for a person

First Posted Date: 2011-08-01

Last Posted Date: 2012-04-19

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 40

Registration Number: NCT01406509

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Phase 2

Completed

Conditions: Immunogenicity
Safety

Interventions: Biological: 160U /0.5ml EV71 Vaccine
Biological: 320U /0.5ml EV71 vaccine
Biological: 640U /0.5ml EV71 vaccine
Biological: (without adjuvant) 640U /0.5ml
Biological: 0/0.5ml placebo

First Posted Date: 2011-07-22

Last Posted Date: 2012-05-31

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 1200

Registration Number: NCT01399853

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Phase 1

Completed

Conditions: Hand, Foot, and Mouth Disease
Enterovirus Infections

Interventions: Biological: 160U /0.5ml
Biological: 320U /0.5ml
Biological: 640U /0.5ml
Biological: 0/0.5ml placebo

First Posted Date: 2011-03-14

Last Posted Date: 2012-01-02

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 360

Registration Number: NCT01313715

Locations: 🇨🇳
Donghai Center for Diseases Control and Prevention, Lianyungang, Jiangsu, China

A Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children

Phase 1

Completed

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: vaccine against EV71 of 320U/0.5ml
Biological: vaccine against EV71 of 160U/0.5ml
Biological: vaccine against EV71 of 640U/0.5ml

First Posted Date: 2010-12-29

Last Posted Date: 2011-06-10

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 100

Registration Number: NCT01267903

Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children

Completed

Conditions: Hand, Foot and Mouth Disease
Anti-EV71
Anti-CVA16

First Posted Date: 2010-12-07

Last Posted Date: 2011-09-14

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 1297

Registration Number: NCT01255124

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines

Phase 2

Completed

Conditions: Hepatitis b

Interventions: Biological: 60mcg/1.0ml recombinant hepatitis B vaccine
Biological: 30mcg/1.0ml recombinant hepatitis B vaccine
Biological: 10mcg/1.0ml recombinant hepatitis B vaccine

First Posted Date: 2010-09-16

Last Posted Date: 2012-04-27

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 1091

Registration Number: NCT01203319

The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates

Phase 3

Completed

Conditions: Virus Disease
DNA Virus Infections
Hepadnaviridae Infections

Interventions: Biological: Experimental recombinant hepatitis B vaccine, HBIG
Biological: Active Comparator hepatitis B vaccine
Biological: Experimental recombinant hepatitis B vaccine
Biological: Active Comparator recombinant hepatitis B vaccine.
Biological: Placebo Comparator recombinant hepatitis B vaccine

First Posted Date: 2010-08-17

Last Posted Date: 2010-09-17

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 1740

Registration Number: NCT01183611

Locations: 🇨🇳
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing, Jiangsu, China

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older

Phase 2

Completed

Conditions: Virus Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Influenza
Orthomyxoviridae Infections

Interventions: Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg

First Posted Date: 2009-09-11

Last Posted Date: 2012-09-12

Lead Sponsor: Jiangsu Province Centers for Disease Control and Prevention

Target Recruit Count: 2200

Registration Number: NCT00975572

Locations: 🇨🇳
Taizhou Municipal Center for Disease Control and Prevention, Taizhou, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy